Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

AEMD - Aethlon Medical, Inc. So'nggi Yangiliklar | Finranks

Home

AEMD

A

Aethlon Medical, Inc. (AEMD)

NCM – Real vaqt narxi. Valyuta: USD

2.15

-0.12 (-5.29%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

2.12

-0.03 (-1.40%)

Bozordan keyin: Mar 27, 2026, 6:36 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Advancements in Novel Immunotherapeutics in The Oncology Battle

Advancements in Novel Immunotherapeutics in The Oncology Battle

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - March 24, 2026) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at advancements in novel immunotherapeutics, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications. Advancements in Novel Immunotherapeutics in The Oncology Battle To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/6292/289695_0e46dab6145c8910_001full.jpg Novel immunotherapeutics have transformed oncology, moving away from broad, non-specific treatments toward highly personalized strategies that harness the patient's immune system to precisely target cancer cells.

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

SAN DIEGO, March 24, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review of the second cohort participant data and recommended advancing to the third and final cohort. They also stated that "no safety concerns were noted with Hemopurifier device/procedure".

Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities

Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities

SAN DIEGO, March 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is evaluating a range of strategic opportunities and has engaged Maxim Group LLC ("Maxim") to act as the Company's exclusive financial advisor in connection with this process. The Company engaged Maxim following preliminary inbound interest regarding potential strategic opportunities.

Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th

Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com

Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference. SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET.

Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript

Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript

Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript

Aethlon Medical, Inc. (AEMD) Q3 2026 Earnings Call Transcript

Aethlon Medical, Inc. (AEMD) Q3 2026 Earnings Call Transcript

Aethlon Medical, Inc. (AEMD) Q3 2026 Earnings Call Transcript

Videolar

No Data

There is no data to display

Press-relizlar

Advancements in Novel Immunotherapeutics in The Oncology Battle

Advancements in Novel Immunotherapeutics in The Oncology Battle

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - March 24, 2026) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at advancements in novel immunotherapeutics, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications. Advancements in Novel Immunotherapeutics in The Oncology Battle To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/6292/289695_0e46dab6145c8910_001full.jpg Novel immunotherapeutics have transformed oncology, moving away from broad, non-specific treatments toward highly personalized strategies that harness the patient's immune system to precisely target cancer cells.

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

SAN DIEGO, March 24, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review of the second cohort participant data and recommended advancing to the third and final cohort. They also stated that "no safety concerns were noted with Hemopurifier device/procedure".

Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities

Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities

SAN DIEGO, March 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is evaluating a range of strategic opportunities and has engaged Maxim Group LLC ("Maxim") to act as the Company's exclusive financial advisor in connection with this process. The Company engaged Maxim following preliminary inbound interest regarding potential strategic opportunities.

Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.